Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Iversen

Showing results (191-200 of 226) with videos related to

Pageof 23
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|February 4, 2014
Inflammatory cytokines break down intrinsic immunological tolerance of human primary keratinocytes to cytosolic DNASrikanth Chiliveru, Stine H Rahbek, Simon K Jensen, et al.
Nature Communications|October 21, 2018
Dimethyl fumarate is an allosteric covalent inhibitor of the p90 ribosomal S6 kinasesJacob Lauwring Andersen, Borbala Gesser, Erik Daa Funder, et al.
American Heart Journal|June 3, 2008
Hospital-based comprehensive cardiac rehabilitation versus usual care among patients with congestive heart failure, ischemic heart disease, or high risk of ischemic heart disease: 12-month results of a randomized clinical trialAnn-Dorthe Olsen Zwisler, Anne Merete Boas Soja, Søren Rasmussen, et al.
Dermatology (Basel, Switzerland)|April 27, 2020
MicroRNA-93 Targets p21 and Promotes Proliferation in Mycosis Fungoides T CellsMaria Gluud, Simon Fredholm, Edda Blümel, et al.
Toxicologic Pathology|August 4, 2005
Generalized cellular hypertrophy is induced by a dual-acting PPAR agonist in rat urinary bladder urothelium in vivoMartin B Oleksiewicz, Inger Thorup, Henriette S Nielsen, et al.
Acta Dermato-Venereologica|August 18, 2025
Adverse Events and Immune Response in Psoriasis Patients Receiving Interleukin-17 InhibitorsChristopher Willy Schwarz, Charlotte Näslund-Koch, Claus Zachariae, et al.
The Lancet Regional Health. Europe|July 19, 2023
Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis-a randomized controlled trial (PSORRO)Mette Gyldenløve, Howraman Meteran, Jennifer A Sørensen, et al.
EMBO Molecular Medicine|February 21, 2024
Rare coding variants in NOX4 link high ROS levels to psoriatic arthritis mutilansSailan Wang, Pernilla Nikamo, Leena Laasonen, et al.
Blood|February 22, 2007
Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphomaYoun H Kim, Madeleine Duvic, Erik Obitz, et al.
Journal of the American Academy of Dermatology|March 25, 2026
Impact of early treatment of psoriasis on disease recurrence - Results from the STEPIn studyLars Iversen, Richard G Langley, Johann E Gudjonsson, et al.
Pageof 23

Showing results (191-200 of 226) with videos related to

Sort By:
Pageof 23
Journal of Immunology (Baltimore, Md. : 1950)|February 4, 2014
Inflammatory cytokines break down intrinsic immunological tolerance of human primary keratinocytes to cytosolic DNASrikanth Chiliveru, Stine H Rahbek, Simon K Jensen, et al.
Nature Communications|October 21, 2018
Dimethyl fumarate is an allosteric covalent inhibitor of the p90 ribosomal S6 kinasesJacob Lauwring Andersen, Borbala Gesser, Erik Daa Funder, et al.
American Heart Journal|June 3, 2008
Hospital-based comprehensive cardiac rehabilitation versus usual care among patients with congestive heart failure, ischemic heart disease, or high risk of ischemic heart disease: 12-month results of a randomized clinical trialAnn-Dorthe Olsen Zwisler, Anne Merete Boas Soja, Søren Rasmussen, et al.
Dermatology (Basel, Switzerland)|April 27, 2020
MicroRNA-93 Targets p21 and Promotes Proliferation in Mycosis Fungoides T CellsMaria Gluud, Simon Fredholm, Edda Blümel, et al.
Toxicologic Pathology|August 4, 2005
Generalized cellular hypertrophy is induced by a dual-acting PPAR agonist in rat urinary bladder urothelium in vivoMartin B Oleksiewicz, Inger Thorup, Henriette S Nielsen, et al.
Acta Dermato-Venereologica|August 18, 2025
Adverse Events and Immune Response in Psoriasis Patients Receiving Interleukin-17 InhibitorsChristopher Willy Schwarz, Charlotte Näslund-Koch, Claus Zachariae, et al.
The Lancet Regional Health. Europe|July 19, 2023
Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis-a randomized controlled trial (PSORRO)Mette Gyldenløve, Howraman Meteran, Jennifer A Sørensen, et al.
EMBO Molecular Medicine|February 21, 2024
Rare coding variants in NOX4 link high ROS levels to psoriatic arthritis mutilansSailan Wang, Pernilla Nikamo, Leena Laasonen, et al.
Blood|February 22, 2007
Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphomaYoun H Kim, Madeleine Duvic, Erik Obitz, et al.
Journal of the American Academy of Dermatology|March 25, 2026
Impact of early treatment of psoriasis on disease recurrence - Results from the STEPIn studyLars Iversen, Richard G Langley, Johann E Gudjonsson, et al.
Pageof 23